Antiviral Drugs Market Size To Reach $62.05 Billion By 2030

Antiviral Drugs Market Growth & Trends

The global antiviral drugs market size is expected to reach USD 62.05 billion by 2030, registering a CAGR of -1.99% from 2023 to 2030, according to a new report by Grand View Research, Inc. This is attributed to the rising prevalence of viral diseases and growing government initiatives pertaining to the development of novel therapeutics to reduce the spread of infections. Furthermore, an increase in R&D efforts and the expansion of more recent & updated details, such as vaccinations and combined therapy, are projected to propel the growth of the market. Potential viral pandemics highlight the need for broad-spectrum antiviral drugs, such as direct-acting antivirals, that can be immediately deployed on a massive scale to halt viral spread until suitable vaccinations are created. Introducing blockbuster therapeutics for antiviral drugs has been transformative in treating various viral infections.

These drugs have demonstrated significant efficacy, widespread use, and substantial revenue generation for pharmaceutical companies.One prominent example is the introduction of Direct-acting Antivirals (DAAs) for the treatment of hepatitis C drugs, such as Sovaldi (sofosbuvir), Harvoni (ledipasvir/sofosbuvir), and Epclusa (sofosbuvir/velpatasvir), revolutionized the field by providing high cure rates, shorter treatment durations, and fewer side effects compared to previous therapies. These drugs achieved blockbuster status due to their effectiveness in curing hepatitis C and addressing a significant unmet medical need. Government initiatives for antiviral drugs include funding for R&D, streamlining regulatory processes for approval and emergency use authorizations, strategic stockpiling for preparedness, and collaborations with industry & academic institutions to accelerate development and ensure accessibility of effective antiviral treatments.

For instance, in May 2022, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, granted around USD 577 million to launch nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern. Moreover, increasing collaborations between government bodies and key players are anticipated to fuel the growth of R&D activities for developing novel antiviral drugs. For instance, in June 2021, Merck & Co., Inc. entered into a procurement agreement with the U.S. government for molnupiravir, an investigational antiviral for COVID-19 treatment. According to the agreement, the company will receive USD 1.2 billion to supply around 1.7 million drug courses to the U.S. government if molnupiravir receives emergency use authorization or approval by the U.S. FDA.

Furthermore, market entities are undertaking strategic initiatives to address the growing demand for clinical tests. Major players are involved in the acquisition of regional players to strengthen their position in the market. Thus, there is significant competition among players in this region. Players in the market are focusing on developing new products. For instance, as of June 2023, over 900 studies are ongoing in phases 2, 3, and 4 of clinical trials for antiviral drug development. Moreover, in April 2023, PharmaMar initiated the Nereida clinical trial using plitidepsin for the treatment of immunosuppressed patients suffering from COVID-19, with trials being approved in Spain, Italy, France, Poland, Hungary, Greece, and Portugal.

 Request a free sample copy or view report summary: Antiviral Drugs Market

Antiviral Drugs Market Report Highlights

• The branded type segment dominated the market in 2022 as they are widely adopted due to their proven efficacy, safety profile, and endorsement by healthcare authorities

• On the basis of drug class, the protease inhibitors segmentdominated the market in 2022 owing to the rising need for effective therapeutics due to the increasing prevalence of chronic diseases, such as HIV/AIDS

• Based on distribution channel, the hospital pharmacy segment held the largest market share in 2022owing to an increasing number of people suffering from diseases, a rapidly aging population, and a growing number of hospitalizations

• North America has established a strong regional position in the market due to the presence of well-established healthcare infrastructure,a high prevalence of viral diseases, and rapid advancements in therapeutics

Antiviral Drugs Market Segmentation

Grand View Research has segmented the global antiviral drugs market on the basis of type, drug class, distribution channel, application, and region:

Antiviral Drugs Type Outlook (Revenue, USD Million, 2018 - 2030)

• Branded

• Generics

Antiviral Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• DNA Polymerase Inhibitors

• Reverse Transcriptase Inhibitors

• Protease Inhibitors

• Neuraminidase Inhibitors

• Others

Antiviral Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

Antiviral Drugs Application Outlook (Revenue, USD Million, 2018 - 2030)

• HIV

• Hepatitis

• Herpes

• Influenza

• Others

Antiviral Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

• U.S.

• Canada

• Europe

• U.K.

• Germany

• France

• Italy

• Spain

• Denmark

• Sweden

• Norway

• Asia Pacific

• Japan

• China

• India

• South Korea

• Australia

• Thailand

• Latin America

• Brazil

• Mexico

• Argentina

• Middle East & Africa

• South Africa

• Saudi Arabia

• UAE

• Kuwait

List of Key Players in Antiviral Drugs Market

• F. Hoffmann-La Roche Ltd.

• GSK plc.

• AbbVie, Inc.

• Merck & Co., Inc.

• Johnson & Johnson Services, Inc.

• Bristol-Myers Squibb Company

• Cipla Inc.

• Aurobindo Pharma

• Dr. Reddy’s Laboratories Ltd.